Cosmos Health マネジメント

マネジメント基準チェック /24

Cosmos Healthの CEO はGreg Siokasで、 Feb2016年に任命され、の在任期間は 8.75年です。の年間総報酬は$ 2.80Mで、 35.7%給与と64.3%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の15.8%を直接所有しており、その価値は€ 2.37M 。経営陣と取締役会の平均在任期間はそれぞれ6.4年と4.3年です。

主要情報

Greg Siokas

最高経営責任者

US$2.8m

報酬総額

CEO給与比率	35.7%
CEO在任期間	8.8yrs
CEOの所有権	15.8%
経営陣の平均在職期間	6.4yrs
取締役会の平均在任期間	4.3yrs

経営陣の近況

Recent updates

CEO報酬分析

Cosmos Health の収益と比較して、Greg Siokas の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$34m
Jun 30 2024	n/a	n/a	-US$29m
Mar 31 2024	n/a	n/a	-US$27m
Dec 31 2023	US$3m	US$1m	-US$26m
Sep 30 2023	n/a	n/a	-US$43m
Jun 30 2023	n/a	n/a	-US$42m
Mar 31 2023	n/a	n/a	-US$59m
Dec 31 2022	US$600k	n/a	-US$64m
Sep 30 2022	n/a	n/a	-US$35m
Jun 30 2022	n/a	n/a	-US$35m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	n/a	n/a	-US$16m
Sep 30 2021	n/a	n/a	-US$7m
Jun 30 2021	n/a	n/a	-US$5m
Mar 31 2021	n/a	n/a	-US$870k
Dec 31 2020	n/a	n/a	US$821k
Sep 30 2020	n/a	n/a	US$2m
Jun 30 2020	n/a	n/a	-US$648k
Mar 31 2020	n/a	n/a	-US$4m
Dec 31 2019	n/a	n/a	-US$3m
Sep 30 2019	n/a	n/a	-US$13m
Jun 30 2019	n/a	n/a	-US$9m
Mar 31 2019	n/a	n/a	-US$6m
Dec 31 2018	n/a	n/a	-US$9m
Sep 30 2018	n/a	n/a	-US$2m
Jun 30 2018	n/a	n/a	-US$6m
Mar 31 2018	n/a	n/a	-US$7m
Dec 31 2017	US$250k	n/a	-US$6m

報酬と市場: Gregの総報酬 ($USD 2.80M ) は、 German市場 ($USD 471.55K ) の同規模の企業の平均を上回っています。

報酬と収益: Gregの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Greg Siokas (59 yo)

8.8yrs

在職期間

US$2,800,000

報酬

Mr. Grigorios Siokas, also known as Greg, has been the Chairman and Chief Executive Officer of Cosmos Health Inc. (formerly known as Cosmos Holdings Inc.) since February 26, 2016 and served as its Presiden...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Grigorios Siokas	Chairman & CEO	8.8yrs	US$2.80m	15.8% € 2.4m
Georgios Terzis	Chief Financial Officer	4yrs	US$435.48k	3.61% € 542.7k
Nikolaos Bardakis	Chief Operating Officer	1.8yrs	US$49.58k	0.25% € 38.1k
Demetrios Demetriades	Secretary & Independent Director	10.8yrs	US$32.65k	0.11% € 16.9k

6.4yrs

平均在職期間

57yo

平均年齢

経験豊富な経営陣: V67Aの経営陣は経験豊富で経験豊富です（平均在職期間は6.4年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Grigorios Siokas	Chairman & CEO	8.8yrs	US$2.80m	15.8% € 2.4m
Demetrios Demetriades	Secretary & Independent Director	10.8yrs	US$32.65k	0.11% € 16.9k
Manfred Ziegler	Independent Director	1.9yrs	US$30.15k	0.11% € 16.9k
Peter Goldstein	Member of Advisory Board	no data	データなし	データなし
Anastasios Tzikas	Member of Advisory Board	6yrs	データなし	データなし
Anastasios Aslidis	Independent Director	2.6yrs	US$130.60k	0.23% € 33.8k
John Hoidas	Independent Director	8yrs	US$32.65k	0.11% € 16.9k
Panagiotis Zoumboulakis	Member of Advisory Board	2.3yrs	データなし	データなし
Suhel Bhutawala	Independent Director	1.2yrs	US$83.40k	0.17% € 25.4k
Vassos Efthymiadis	Member of Advisory Board	no data	データなし	データなし
Ioannis Dedes	Member of Advisory Board	no data	データなし	データなし

4.3yrs

平均在職期間

59yo

平均年齢

経験豊富なボード: V67Aの取締役会は経験豊富であると考えられます ( 4.3年の平均在任期間)。

Cosmos Health マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Cosmos Health Inc., Annual General Meeting, Nov 19, 2024

High number of new and inexperienced directors

Cosmos Health Inc. Announces Executive and Board Changes

Cosmos Health Inc., Annual General Meeting, Sep 18, 2023

Cosmos Health Inc. Appoints Nikos Bardakis as Chief Operating Officer

Cosmos Holdings Inc., Annual General Meeting, Dec 02, 2022

Recent updates

Third quarter 2024 earnings released: EPS: US$0.22 (vs US$0.27 loss in 3Q 2023)

Cosmos Health Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price

Cosmos Health Inc., Annual General Meeting, Nov 19, 2024

Cosmos Health Inc. Provides Earnings Guidance for the Year 2024, 2025, 2026, 2027

Cosmos Health Regains Full Compliance with Nasdaq Listing Requirements

Cosmos Health Inc. announced delayed 10-Q filing

Cosmos Health Receives Additional Delinquency Letter from Nasdaq Regarding Late Filings of its Forms 10-K and 10-Q

Cosmos Health Inc. announced delayed 10-Q filing

Cosmos Health Inc. announced delayed annual 10-K filing

Cosmos Health Inc. Receives Non-Compliance Letter from Nasdaq Related to Minimum Bid Price

Cosmos Health Inc. Commences Development of Cloudscreen 2.0 the New Iteration of Its Next Generation AI Drug Repurposing Platform

Cosmos Health Inc. Receives Regulatory Approval to Sell Sky Premium Life Products in UAE Nutritional Supplements Market

New major risk - Financial position

Cosmos Health Inc. has filed a Follow-on Equity Offering in the amount of $5.049535 million.

High number of new and inexperienced directors

Cosmos Health Inc. (NasdaqCM:COSM) completed the acquisition of Cloudscreen.

Cosmos Health Inc. announced delayed 10-Q filing

Cosmos Health Inc. (NasdaqCM:COSM) signed an agreement to acquire Cloudscreen.

Cosmos Health Inc. Announces Executive and Board Changes

Cosmos Health Inc. Provides Earnings Guidance for the Year 2023

Cosmos Health Inc., Annual General Meeting, Sep 18, 2023

Cosmos Health Inc. announced delayed 10-Q filing

Second quarter 2023 earnings released: US$0.091 loss per share (vs US$23.37 loss in 2Q 2022)

Cosmos Health Inc. announced that it has received $5.25 million in funding

Cosmos Holdings Inc. (NasdaqCM:COSM) acquired 100% stakes in Cana Laboratories S.A. for approximately $1.67 million.

Cosmos Health Inc. Launches Terra Creta

Cosmos Health Inc. entered into letter of intent agreement to acquire Docpharm Arzneimittelvertrieb Gmbh & Co. Kg Auf Aktien.

Cosmos Health Inc. announced delayed 10-Q filing

Full year 2022 earnings released: US$33.16 loss per share (vs US$23.74 loss in FY 2021)

Cosmos Health Inc. Appoints Nikos Bardakis as Chief Operating Officer

Cosmos Health Inc. (NasdaqCM:COSM) announces an Equity Buyback for $3 million worth of its shares.

Cosmos Health Inc. announced that it has received $32.52568 million in funding

Cosmos Health Inc. announced that it has received $32.52568 million in funding

Cosmos Health Inc. has completed a Follow-on Equity Offering in the amount of $32.52568 million.

Cosmos Health Inc. has completed a Follow-on Equity Offering in the amount of $32.52568 million.

Cosmos Health Enters the Development Phase for CCX0722, an Innovative Product for Obesity and Weight Management

Third quarter 2022 earnings released: US$0.077 loss per share (vs US$0.11 loss in 3Q 2021)

Cosmos Holdings Inc., Annual General Meeting, Dec 02, 2022

Cosmos Holdings Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million.

Cosmos Holdings Inc. (NasdaqCM:COSM) entered into a non-binding letter of intent agreement to acquire ZipDoctor, Inc from American International Holdings Corp. (OTCPK:AMIH).

Cosmos Holdings Inc. announced delayed 10-Q filing

Cosmos Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price

Cosmos Holdings Inc. (NasdaqCM:COSM) entered into a binding letter of intent to acquire Cana Laboratories S.A.

Cosmos Holdings, Inc. Appoints Dr. Panagiotis Zoumpoulakis to its Advisory Board

Cosmos Holdings Inc. (NasdaqCM:COSM) entered into an agreement to acquire product portfolio of Life NLB, Ltd.

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24